Skip to content
Tutorials Center
My learning

Topics

Lesson 16 of 48 ยท Pharmacokinetics

Chapter 3 review: pharmacokinetics

Review chapter 3: absorption, distribution, metabolism, elimination, key formulas for F, Vd, CL and half-life, a renal dose-adjustment calculator and a ten-question quiz.

You have followed a dose from the mouth to the kidney. This review collects the numbers and formulas of Chapter 3 on a single page so that you can see how they fit: bioavailability sets what gets in, volume sets where it goes, clearance sets how fast it leaves, and half-life and steady state follow. Use the table to check your recall and the calculator to practice a typical applied problem, then take the long quiz.

Three cards summarising ADME, the key pharmacokinetic quantities and the rules of thumb for steady state
Chapter 3 in one picture: ADME, four key numbers, and rules of thumb.

What you will learn

  • A single-page summary of the formulas and ideas of Chapter 3.
  • How the four main quantities F, Vd, CL and tยฝ relate to each other.
  • How reduced kidney function changes dosing, with a worked calculator.

Recap table

Quantity or idea Formula or key fact Lesson
Passive absorption Unionized fraction from pH and pKa; surface area often dominates Absorption
Bioavailability F = fa x Fg x (1 - Eh); F = AUC(oral) / AUC(IV) Absorption
Volume of distribution Vd = amount in body / concentration; loading dose = Vd x Ctarget / F Distribution
Protein binding Only free drug is active; matters most when more than 90% bound Distribution
Metabolism Phase I (CYP oxidation) and phase II (conjugation); inducers lower, inhibitors raise levels Metabolism
Zero-order kinetics Rate approaches Vmax at high concentration; Css rises steeply with dose Metabolism
Clearance CL = rate of elimination / C; sum of organ clearances Elimination
Half-life tยฝ = 0.693 x Vd / CL; about 5 half-lives to wash out Elimination
Steady state Css = F x Dose / (CL x tau); reached in about 4 to 5 half-lives Elimination

How the quantities connect

Vd and CL are independent properties of the drug and the patient, and half-life is derived from them. This is why you can reason in a chain.

  • A patient with kidney disease has a lower CL for a renally cleared drug. The half-life rises, steady state takes longer, and the average concentration at the same dose rises. To keep the same level, lower the maintenance dose or lengthen the interval.
  • A patient with low albumin has a higher free fraction of an acidic, highly bound drug. Total concentration may look normal while the free (active) concentration is high.
  • A patient given an enzyme inducer has a higher CL for a drug cleared by that enzyme, so the average concentration falls, and the dose may have to be increased until the inducer is stopped.
  • A drug given by mouth rather than IV has F below 1, so the oral dose must be larger for the same AUC.

Try it

When a drug is cleared mainly by the kidney, a common approach is to estimate the creatinine clearance (CrCl) using the Cockcroft-Gault equation, then scale the dose. The code below does this for a fictional drug that is 80% excreted unchanged by the kidney. It uses the Kiley-Dettli style adjustment: the dose factor is 1 - fe x (1 - CrCl/120). This illustrates the reasoning only; real adjustments come from product labels and clinical references.

Python Estimating CrCl and scaling a dose (teaching example)

Press Run (or Ctrl + Enter) to see the result here.

Program input ยท what you'd type while the program runs

Type the answers before you press Run, one per line. Each time the program reads a line (with input()), it gets the next line from this box.

The second exercise strings together bioavailability, volume and clearance to design a regimen for an imaginary oral drug.

Python From target concentration to a regimen

Press Run (or Ctrl + Enter) to see the result here.

Program input ยท what you'd type while the program runs

Type the answers before you press Run, one per line. Each time the program reads a line (with input()), it gets the next line from this box.

Check your understanding

Quick check ยท 10 questions

of 10 answered You scored / 10 ยท perfect!

  1. 1. A drug has an oral bioavailability of 25%. Compared with the IV dose that gives the same AUC, the oral dose must be about

    F = 0.25, so you need 1 / 0.25 = 4 times the IV dose.
  2. 2. Which pair of quantities determines half-life?

    t1/2 = 0.693 x Vd / CL.
  3. 3. A drug with a large volume of distribution is poorly removed by dialysis because

    Dialysis cleans blood. If little of the drug is in blood, little is removed.
  4. 4. An enzyme inhibitor is added to a drug cleared mainly by that enzyme. What happens to the average steady-state concentration?

    Clearance falls, so Css = F x Dose / (CL x tau) rises.
  5. 5. A patient takes 150 mg every 6 h of a drug with F = 1 and CL = 10 L/h. What is the average steady-state concentration?

    150 / (10 x 6) = 2.5 mg/L.
  6. 6. A drug has a half-life of 10 h. About how long until it is effectively washed out (5 half-lives)?

    5 x 10 h = 50 h.
  7. 7. Which statement about first-pass metabolism is true?

    Absorbed drug passes the liver before the systemic circulation, where part is metabolized.
  8. 8. Why is phenytoin hard to dose?

    Michaelis-Menten kinetics with a Km in the therapeutic range make levels rise disproportionately.
  9. 9. Which is the best description of clearance?

    CL has units of volume per time.
  10. 10. If a dose is doubled for a first-order drug, the time needed to reach steady state

    It depends only on half-life, which is dose independent for first-order kinetics.

Summary

  • F governs what gets in, Vd where it goes, CL how fast it leaves; tยฝ = 0.693 x Vd / CL and Css = F x Dose / (CL x tau).
  • Disease, genes, other drugs and the route all shift these quantities in predictable directions.
  • About five half-lives are needed to wash out a drug or reach steady state; loading doses speed the start.
  • Renal dose adjustment scales the dose with creatinine clearance for drugs cleared by the kidney.

Next: Chapter 4 overview: pharmacodynamics and dose-response